Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different stages, particularly NASH, is important for both potential reversibility and limitation of complications. Liver biopsy remains the clinical standard for definitive diagnosis. Diagnostic tools minimizing the need for invasive procedures or that add information to histologic data are important in novel management strategies for the growing epidemic of NAFLD. We describe an "omics" approach to detecting a reproducible signature of lipid metabolites, aqueous intracellular metabolites, SNPs, and mRNA transcripts in a double-blinded study of patients with different stages of NAFLD that involves profiling liver biopsies, plasma, and urine samples. Using linear discriminant analysis, a panel of 20 plasma metabolites that includes glycerophospholipids, sphingolipids, sterols, and various aqueous small molecular weight components involved in cellular metabolic pathways, can be used to differentiate between NASH and steatosis. This identification of differential biomolecular signatures has the potential to improve clinical diagnosis and facilitate therapeutic intervention of NAFLD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Little evidence is available on circulating phosphatidylinositol and phosphatidylserine, which have been found to be higher in MASL(101, 102) or only in MASH (phosphatidylinositol).108”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“High levels of plasma ceramides are correlated with the severity of MASLD and reflect hepatic ceramide accumulation.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“Plasma saturated/unsaturated fatty acid TAGs have been found to be elevated,102,103 and associated with IR11,104 in individuals with MASLD.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“Patients with MASH have 20% higher ceramide concentrations compared to healthy individuals.100,102,104,117”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“A few studies have also investigated circulating lipidomic species in patients with advanced forms of MASH (F3), fibrosis, and cirrhosis, showing an increase in circulating levels of some ceramides (d18:1/20:0, d18:1/22:0, d18:1/23:0, d18:1/24:1, d18:1/24:0) and a decrease in hexosylceramide,115 some glucosylceramide (d18:1/24:1, d18:1/26:1, 18:1/26:0), SM, PC, LPC, and phosphatidylinositol94,102”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Lipidomics reveals a remarkable diversity of lipids in human plasma
Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m009449 · Cited by 1,341
Self-citation
Cited by
Items 301–374 of 374
Cardiolipin deficiency disrupts electron transport chain and drives steatohepatitis
Brothwell, M. J., Cao, G., Maschek, J. A., Poss, A. M., Peterlin, A. D., Wang, L., Baker, T. B., Shahtout, J. L., Siripoksup, P., Pearce, Q., et al. (2025) · eLife · doi:10.7554/elife.106976 · Cited by 6
“Although extensive clinical and basic research have been conducted in this field, the underlying mechanisms by which fatty liver transitions to MASH remain poorly understood ( Fan and Cao, 2013 ; Gorden et al., 2015 ; Fu et al., 2011 ).”
Makri, E. S., Mouskeftara, T., Gika, H., Xanthopoulos, K., Makri, E., Mavrommatis-Parasidis, P., Tsingotjidou, A., Cheva, A., Goulas, A., & Pοlyzos, S. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199273 · Cited by 3
“In another study of patients with MASLD, PC 38:4 was similarly affected in the liver and serum, as in our study [59].”
Virseda‐Berdices, A., Requena, B., Berenguer, J., Gónzalez-García, J., González-Riaño, C., Díez, C., Hontañón, V., Muñoz-García, P., Fernández‐Rodríguez, A., Barbas, C., et al. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102981 · Cited by 3
Wang, R., Tang, D., Wu, L., Ou, L., Ding, L., Jiang, J., & Wu, Y. (2025) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2025.106873 · Cited by 3
Wipfli, F., Lone, M. A., von Eckardstein, A., Verrijken, A., Francque, S., Weyler, J., Gaal, L. V., Staels, B., & Hornemann, T. (2025) · Metabolomics · doi:10.1007/s11306-025-02359-4 · Cited by 4
“Recent OMICS studies have also linked an atypical class of sphingolipids, 1-deoxysphingolipids (1-deoxySLs), to MASLD, MetS, and T2DM (Gorden et al., 2015 ; Weyler et al., 2020; Othman et al., 2011; Bertea et al., 2010 ).”
InfluentialSourianarayanane, A., Lee, J., Kim, H., & Phinney, B. S. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00749 · Cited by 2
Li, P., Wang, Y., Hu, H., & Sun, B. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1390605 · Cited by 2
“Dysregulated lipid metabolism has been implicated in several diseases, including diabetes, hyperlipidemia, NAFLD, and cancer (Suvitaival et al., 2018; Wang et al., 2019; Gorden et al., 2015; Bia ł ek et al., 2020).”
FIB-4 Score as a Useful Screening Test for Diagnosing Liver Fibrosis
Ahn, K., Kim, J., Kim, Y., Uh, Y., & Yoon, K. J. (2017) · Imsang byeong'ri wa jeongdo gwanri/Journal of laboratory medicine and quality assurance · doi:10.15263/jlmqa.2017.39.1.16 · Cited by 2
“만성간질환의 섬유화를 예측하기 위한 비침습적 검사로 서 간섬유화스캔 이외에도 온혈구 계산결과와 혈청 간기능검 사결과를 이용한 지표들이 고안되었다[14-16].”
Xu, P., Hong, Y., Chen, P., Wang, X., Li, S., Wang, J., Meng, F., Zhou, Z., Shi, D., Li, Z., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.970563 · Cited by 3
“The “gut-liver axis” refers to the bidirectional relationships among intestinal microbiome, intestine, and liver, attracting significant attention due to its involvement with intestinal microbiota in the occurrence and development of non-alcoholic fatty liver disease (NAFLD) (Bajaj and Hylemon, 2018).”
BackgroundInfluentialBrilakis, L., Theofilogiannakou, E., & Lykoudis, P. M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i11.1480 · Cited by 2
“Moreover, increased production of HIF-2 α could induce lipogenesis in the liver[2,14,21].”
Hosoe, S., Katakami, N., Taya, N., Omori, K., Takahara, M., Konya, Y., Obara, S., Hidaka, A., Nakao, M., Takahashi, M., et al. (2025) · Diabetes · doi:10.2337/db25-0099 · Cited by 1
Sourianarayanane, A., Brydges, C. R., & McCullough, A. J. (2025) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.70069 · Cited by 1
Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes
Béland‐Bonenfant, S., Denimal, D., de Barros, J.-P. P., Choubley, H., Rouland, A., Simoneau, I., Duvillard, L., Aho, S., Bouillet, B., Petit, J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70156 · Cited by 2
Cholesterol-containing lipid crystals can directly stiffen the rat steatotic liver before fibrosis
Li, D., Loneker, A. E., Safraou, Y., Ford, J., Mihelc, E. M., Sakane, S., Kisseleva, T., Levental, K. R., Levental, I., Sack, I., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2518060123 · Cited by 4
Murphy, W. A., Kyburz, S., Ho, H. S. S., Loop, M. S., Fallon, J. K., Tiley, J. B., Kralj, T., & Brouwer, K. L. R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1664808 · Cited by 1
Matsumoto, M., Miura, O., Moriya, T., Ogino, H., Hirayama, M., Mitsui, A., Hirayama, T., Ebisuno, Y., Kaneko, M., Satomi, Y., et al. (2026) · Gut Pathogens · doi:10.1186/s13099-026-00813-9 · Cited by 1
“However, studies by Vvedenskaya et al. [53] and Gorden et al. [54] have suggested that phospholipid changes in human MASH are modest, implying that some of the lipidomic signatures in our model may be species-or diet-specific.”
Differential lipid selectivity of StARD phospholipid transporters revealed by native MS
Kirschbaum, C., Lawrence, S. A. S., Bennett, J. L., Ramsay, O. B., Ahmed, Y., El‐Baba, T. J., Vanni, S., & Robinson, C. V. (2026) · Nature Communications · doi:10.1038/s41467-026-76988-1 · Cited by 1
“18b) 44,45 .”
[Frontiers of research on nonalcoholic fatty liver disease].
Shi, J. (2016) · PubMed Central · doi:10.3785/j.issn.1008-9292.2016.01.16 · Cited by 1
Hussein, N. S., Helmy, A. S., Sherif, N. M., Ghanem, H. Z., Gendy, A. E. G. E., & Abdel‐Hamid, A. Z. (2021) · Egyptian Pharmaceutical Journal · doi:10.4103/epj.epj_40_21 · Cited by 1
Yang, M., Jiang, D., Huang, L., Zhang, T., Guo, W., Lin, W., Zhao, J., Yu, W., Peng, L., Hao, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1505309 · Cited by 1
“Dysregulation of glycerophospholipids in the liver plays an important role in the progression mechanism of human hepatic damage (Gorden et al., 2015).”
Clinical Lipidomics: A Critical Approach for Disease Diagnosis and Therapy
Wang, X. (2018) · Translational bioinformatics · doi:10.1007/978-981-13-0620-4_1 · Cited by 1
Martins, A. M. A., Garcia, J. H. P., & Eberlin, M. N. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1651643 · Cited by 1
Кручинина, М. В., Паруликова, М. В., Kurilovich, S. A., Gromov, A. A., Шашков, М. В., Sokolova, A. S., & Кручинин, В. Н. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-191-7-12-22 · Cited by 1
Lamberz, C., Hesse, M., & Kirfel, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.21.427595 · Cited by 1
Lubrecht, J. (2025) · Research Publications (Maastricht University) · doi:10.26481/dis.20250509jl · Cited by 1
Cardiolipin deficiency disrupts electron transport chain to drive steatohepatitisPreprint
Brothwell, M. J., Cao, G., Maschek, J. A., Poss, A. M., Peterlin, A. D., Wang, L., Baker, T., Shahtout, J. L., Siripoksup, P., Pearce, Q., et al. (2025) · eLife · doi:10.7554/elife.106976.1 · Cited by 6
The lipidomics of non-alcoholic fatty liver disease : from in vitro to human studies
Peng, K. (2017) · Minerva Access (University of Melbourne)
The role of MRI in stratifying and evaluating chronic liver disease
Eddowes, P. J. (2018) · University of Birmingham Institutional Research Archive (University of Birmingham)
Naserpour, M., Zabihzadeh, M., Gharibvand, M., Motamedfar, A., Tahmasebi, M., Sina, A. H., & Bahrami, K. (2018) · Journal of Medical Signals & Sensors · doi:10.4103/jmss.jmss_32_18
“The minimum mean FI was −2.49% (FI29) which corresponds to the minimal T 1 weighted pulse sequence (sequence 13 TR = 200 ms, α = 20 ° quantified by method 2 [Table 3].”
InfluentialSaravanakumar, A. (2019) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-saravanakumar-anitha-2019
Health aberrations in children with overweight and obesity: a special focus on the liver
Karnebeek (2020) · Research Publications (Maastricht University) · doi:10.26481/dis.20200109kk
Role of lipid metabolic pathways in the progression of hepatic lipotoxicity
Leamy, A. K. (2015)
Mechanisms of Fibrogenesis in NASH
Pastore, M., Gentilini, A., & Marra, F. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_6
Subramaniam, S., & Nadeau, J. H. (2020) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1517
“, 2009) and obesity and fatty liver diseases (Gorden et al., 2015), both associated with diet and lifestyle with arguably genetic predisposition.”
BackgroundSelf-citationThiele, M. S., Suvitaival, T., Trôst, K., Kim, M. G., de Zawadzki, A., Kjærgaard, M., Rasmussen, D. N., Lindvig, K. P., Israelsen, M. E., Detlefsen, S., et al. (2021) · medRxiv · doi:10.1101/2021.07.13.21260429
“combined liver and plasma lipidomics [13-15].”
BackgroundExercise-Mediated Autophagy and Nonalcoholic Fatty Liver Disease
Li, F., Zou, K., & Chen, N. (2021) · Springer eBooks · doi:10.1007/978-981-16-4525-9_5
Enhancing Hepatic MBOAT7 Expression Does Not Improve Nonalcoholic Steatohepatitis in MicePreprint
Sharpe, M. C., Pyles, K. D., Hallcox, T., Kamm, D. R., Piechowski, M., Fisk, B. A., Albert, C. J., Carpenter, D. H., Ulmasov, B., Ford, D. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.24.485677
“combined from (20, 21), is decreased in HO, NAFL, and NASH compared to NC livers (n=51, 160, 134, and 80, respectively).”
BackgroundLi, J., Huang, Y., Huang, C., Zhao, Y. D., Shi, X., Chen, Z., Wang, L., Han, L., Chen, Z., & Li, X. (2020) · doi:10.21203/rs.3.rs-26934/v1
Serum Metabolome Alterations in Patients With Nonalcoholic Fatty Liver DiseasePreprint
Wang, X., Rao, B., Wang, H., Liu, Z., Liu, S., Ding, S., Zhang, G., Liu, L., Ren, H., Liu, C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3969262
Outtakes from My Journey through the World of LIPID MAPS
Dennis, E. A. (2022) · Molecules · doi:10.3390/molecules27123885
“Its final integrated effort was aimed at developing lipid biomarkers for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and integrating them with other omics approaches [31].”
BackgroundSelf-citationEffect of curcumin and zingiberone on non alcoholic fatty liver disease (NAFLD)
Sharma, V., Sharma, S., Akarshit, Kumar, R., Sharma, P., Mittal, A., Kumar, R., & Sharma, M. (2023) · AIP conference proceedings · doi:10.1063/5.0162870
(2023) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2023.315687
Cong, S., Li, Z., Yu, L., Liu, Y., Hu, Y., Bi, Y., & Cheng, M. (2021) · Figshare · doi:10.6084/m9.figshare.14196627
Cong, S., Li, Z., Yu, L., Liu, Y., Hu, Y., Bi, Y., & Cheng, M. (2021) · Figshare · doi:10.6084/m9.figshare.14196624
Bertran, L., Capellades, J., Abelló, S., & Richart, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4653166/v1
Liang, H., Liu, H., Li, J., Wang, B., Huang, P., Guo, W., Zhuang, B., Liao, L., Li, Q., Wu, X., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002791 · Cited by 1
“Additionally, plasma CER(d18:1/18:0) and CER(d18:1/24:0) were higher in the nonalcoholic steatohepatitis (NASH) patients but lower in the cirrhosis patients compared to steatotic patients and control subjects [24] .”
Self-citationCis-Palmitoleic Acid Regulates Lipid Metabolism via Diacylglycerol Metabolic Shunting
Huang, W.-W., Gao, B., Liu, L., Song, Q., Wei, M., Li, H.-Z., Sun, C.-L., Li, W., Du, W., & Shan, J. (2025) · Foods · doi:10.3390/foods14142504
“Notably, elevated DAG(36:3, 18:1–18:2) was strongly associated with lipotoxicity [40], a key driver that induced hepatocyte injury, inflammation, insulin resistance, and liver disease exacerbation [41].”
Saravanakumar, A., Tierney, C. A., He, W., Jamwal, R., Barlock, B. J., Bush, X., Johnson, J. G., Rodrigues, D. A., & Akhlaghi, F. (2025) · Current Drug Metabolism · doi:10.2174/0113892002381234250727004847
Novel prostaglandin and isoprostane panel for evaluating Wilson’s Disease
Polat, M. Ç. A. Ü. L. T. İ. Ç. G., Durukan, B. M., İsrafilov, S., Çakmaklı, G. Y., İdilman, İ. S., Dağ, O., Karçaaltıncaba, M., Sökmensüer, C., Elibol, B., Balaban, Y. H., et al. (2025) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2024-0330
“…PGE 2 , PGD 2 , and PGF 2 α , in fl uence immune modulation, allergic responses, and neurological functions, while isoprostanes such as iPF 2 α - III, 2,3-dinor-iPF 2 α -III, and fi ve-iPF 2 α -VI serve as indicators of oxidative stress, renal function, and cardiovascular damage [23, 35 – 38].”
Marian, O. C., Min, D., Baker, C. J., Hodgkins, C. J., Gerofi, J. A., Wang, X., Johnson, N. A., Don, A. S., & Twigg, S. M. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00171.2025 · Cited by 1
Flóres, Y. N., Amoon, A. T., Su, B., Velázquez‐Cruz, R., Ramírez-Palacios, P., Salmerón, J., Rivera‐Paredez, B., Sinsheimer, J. S., Lusis, A. J., Huertas-Vazquez, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16780913
Flóres, Y. N., Amoon, A. T., Su, B., Velázquez‐Cruz, R., Ramírez-Palacios, P., Salmerón, J., Rivera‐Paredez, B., Sinsheimer, J. S., Lusis, A. J., Huertas-Vazquez, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16780916
Flóres, Y. N., Amoon, A. T., Su, B., Velázquez‐Cruz, R., Ramírez-Palacios, P., Salmerón, J., Rivera‐Paredez, B., Sinsheimer, J. S., Lusis, A. J., Huertas-Vazquez, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16780919
Cong, S., Li, Z., Yu, L., Liu, Y., Hu, Y., Bi, Y., & Cheng, M. (2021) · Figshare · doi:10.6084/m9.figshare.14196630
Associations of lipids with diseases in large cohort studies and randomized trials
Kaur, R. P., & Palagati, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19116-9.00040-3
Beyond lipid homochirality: Analytical strategies and biological implications
Shukla, V., Guaraca-Medina, T. A., Lodi, A., & Tiziani, S. (2026) · Talanta · doi:10.1016/j.talanta.2026.129464
Cen, Y., Zhiyu, P., Zi, X., Peng, S., Liu, R., Yang, B., Fan, Y., Yang, J., Zhao, Y., & Zhang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1731772 · Cited by 1
“The severity of NAFLD has been linked to increases in oxidative stress and a proin fl ammatory state (25).”
InfluentialThe roles of endoplasmic reticulum stress and Bax inhibitor-1 in non-alcoholic fatty liver disease
Lebeaupin, C. (2018) · theses.fr (ABES) · doi:10.70675/de500ab2z3c59z484dz8f58z7c3173626c42
Homéostasie des céramides et hépatopathies métaboliques
Régnier, M. (2018) · theses.fr (ABES) · doi:10.70675/2fb92711z373cz4b27z8082z7aa3f8930e63 · Cited by 1
Rôle des sphingolipides hépatiques dans la physiopathologie du diabète de type 2
Lachkar, F. (2022) · theses.fr (ABES) · doi:10.70675/2f1ce169zade5z47ccz96caz55bf77edab09
Rôle de la kinase ATR dans la progression de la stéatose hépatique non alcoolique
Saroul-Aïnama, M. (2022) · theses.fr (ABES) · doi:10.70675/1fc5906az1637z451czab81z7529e034be63
Byeon, S. K., Sabu, S., Tietz-Bogert, P. S., Balan, J., O’Hara, S. P., LaRusso, N. F., & Pandey, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-45651-6
Liu, H., Xu, T., Guo, Y., Zhou, X., Yan, C., Zhu, B., & Xie, Y. (2026) · Virulence · doi:10.1080/21505594.2026.2739091
“Recent research has focused on noninvasive biomarkers to differentiate NAFLD, NASH, and liver fibrosis in general population [47,48].”
Hepatic amino acid metabolism in liver, cardiovascular, kidney and metabolic diseases
Flam, E. L., Tailleux, A., Haas, J. T., & Staels, B. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120756
Lv, J., Wang, J.-H., Wang, Y., Huang, J., Chen, F.-R., Fang, S., Wang, X.-J., Li, Z.-T., Shi, Y.-P., & Guo, L. (2026) · International Microbiology · doi:10.1007/s10123-026-00845-w
“…atherosclerotic pathogenesis, have long dominated dyslipidemia research (Borén et al., 2020; Ference et al., 2019 ; Fernández-Friera et al., 2017; Gorden et al., 2015; Meikle et al., 2014; Morales et al., 2022), accumulating evidence underscores the clinical significance of TG metab - olism…”
Sharma, J., & Dey, P. (2026) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6c00049
Miyakami, Y., Matsumoto, M., Ichimura‐Shimizu, M., Yoshimura, K., Tsutsui, A., Tsuchiyama, Y., Takaguchi, K., Takeda, S., & Tsuneyama, K. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45009
France, T. L., Javaid, A., Juarez-Leon, K. S., Reyes, D. C., Deme, P., Haughey, N. J., & McFadden, J. W. (2026) · Journal of Dairy Science · doi:10.3168/jds.2026-28852 · Cited by 1
De, A. J., Upadhyaya, B., & Aich, P. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00163.2026
Mai, K., Jiang, J., Ma, X., Huang, W., & Xia, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189680
3PM-Guided Metabolic Disease Management
Smokovski, I., & Tariq, R. (2026) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-3-032-32838-0_16
Boutari, C., Charalampidis, K., Sideras, L., Sinakos, E., & Goulis, I. (2026) · Life · doi:10.3390/life16101656
“Genetic variants such as PNPLA3 and TM6SF2, together with circulating proteomic, metabolomic, lipidomic, hepatokine, and inflammatory signatures, may help define mechanistic subphenotypes [32,140,141].”
Khan, A., Rajan, Malakar, D., Maan, K., Biswas, S., Sheikh, S. S., Bajaj, A., Shalimar, S., Gupta, I., & Dasgupta, U. (2026) · Communications Health · doi:10.1038/s44528-026-00039-w
Metadata
- Authors
- Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., Duan, J., Sullards, M. C., Leiker, T. J., Barkley, R. M., Quehenberger, O., Armando, A. M., Milne, S. B., Mathews, T. P., Armstrong, M. D., Li, C., Melvin, W. V., Clements, R. H., Washington, M. K., Mendonsa, A. M., Witztum, J. L., Guan, Z., Glass, C. K., Murphy, R. C., Dennis, E. A., Merrill, A. H., Russell, D. W., Subramaniam, S., & Brown, H. A.
- Affiliations
- Vanderbilt University Medical Center (US)
- University of California San Diego (US)
- The University of Texas Southwestern Medical Center (US)
- Georgia Institute of Technology (US)
- University of Colorado Denver (US)
- Duke Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Subramaniam, Shankar
- Brown, H.Alex
- ORCID
- Fahy, Eoin
- Maurya, Mano R.
- Gupta, Shakti
- Spann, Nathanael J.
- McDonald, Jeffrey G.
- Duan, Jingjing
- Barkley, Robert M.
- Quehenberger, Oswald
- Armando, Aaron M.
- Milne, Stephen B.
- Mathews, Thomas P.
- Washington, M.Kay
- Witztum, Joseph L.
- Guan, Ziqiang
- Glass, Christopher K.
- Murphy, Robert C.
- Dennis, Edward A.
- Merrill, Alfred H.
- Russell, David W.
- Subramaniam, Shankar
- Brown, H.Alex
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 56
- Issue
- 3
- Pages
- 722-736
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4340319
- OpenAlex
- W2134541386
- Cited by
- 372
- References
- 73
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 38 · 2023: 34 · 2022: 34 · 2021: 56 · 2020: 42 · 2019: 32 · 2018: 25 · 2017: 20 · 2016: 21 · 2015: 11
- FWCI
- 20.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2040 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL106579)
- National Institute of Mental Health (T32MH093366)
- National Institute of General Medical Sciences (U54GM069338, R24GM107784, GM U54 069338)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK074868, P30DK058404)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, steatosis, disease progression, lipidomics, plasma metabolites, biomarkers, glycerophospholipids, sphingolipids, sterols, liver biopsy, diagnostic signature, NAFLD staging
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Biomarkers, Polymorphism, Single Nucleotide, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.